Autopsy report · NCT04718961

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

“Due to company's assessment of enrollment feasibility.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 11 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 1 year 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mirum Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Intrahepatic Cholestasis of Pregnancy

Interventions

Volixibat; Placebo

Participants

4

Sites

20

Countries

New Zealand, United Kingdom, United States

Trials that died the same way

• Proton Radiation Therapy for Pituitary Adenoma
  “Due to slow enrollment and feasibility issues.” (77% match in meaning)
• Doravirine and Weight Gain in Antiretroviral Naive
  “Due to No/Low enrollment” (76% match in meaning)
• Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)
  “due to low enrollment” (73% match in meaning)
• Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease
  “Enrollment challenges.” (72% match in meaning)
• FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients
  “Due to lower than anticipated enrollment” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.